Journal
NATURE BIOTECHNOLOGY
Volume 33, Issue 8, Pages 853-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.3294
Keywords
-
Categories
Funding
- McEwen Centre for Regenerative Medicine
- Canadian Institutes of Health Research [MOP133620, MOP:97954, GPG:102171]
- University Health Network Multi-Organ Transplant Program Academic Enrichment Fund
- Astellas Pharma Canada
- Alagille Syndrome Alliance
- SickKids Research Institute
- Rare Disease Foundation
- Childhood Liver Disease Research and Education Network
- National Institute of Diabetes, Digestive and Kidney Diseases [U01 DK062453]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK062453] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Although bile duct disorders are well-recognized causes of liver disease, the molecular and cellular events leading to biliary dysfunction are poorly understood. To enable modeling and drug discovery for biliary disease, we describe a protocol that achieves efficient differentiation of biliary epithelial cells (cholangiocytes) from human pluripotent stem cells (hPSCs) through delivery of developmentally relevant cues, including NOTCH signaling. Using three-dimensional culture, the protocol yields cystic and/or ductal structures that express mature biliary markers, including apical sodium-dependent bile acid transporter, secretin receptor, cilia and cystic fibrosis transmembrane conductance regulator (CFTR). We demonstrate that hPSC-derived cholangiocytes possess epithelial functions, including rhodamine efflux and CFTR-mediated fluid secretion. Furthermore, we show that functionally impaired hPSC-derived cholangiocytes from cystic fibrosis patients are rescued by CFTR correctors. These findings demonstrate that mature cholangiocytes can be differentiated from hPSCs and used for studies of biliary development and disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available